Search alternatives:
liver » lives (Expand Search)
decrease » decreased (Expand Search), increase (Expand Search)
Showing 1 - 20 results of 409 for search '(( significantly ((liver disease) OR (larger decrease)) ) OR ( significant decrease decrease ))', query time: 0.12s Refine Results
  1. 1
  2. 2

    A slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity by Wesam S. Ahmed (10170053)

    Published 2024
    “…Here, we combined molecular dynamics (MD) simulation and mutational analysis to show that the R162A mutation results in a decreased but stable <u>bioluminescence </u>activity of NLuc in living cells and in vitro. …”
  3. 3

    apoA2 correlates to gestational age with decreased apolipoproteins A2, C1, C3 and E in gestational diabetes by Manjunath Ramanjaneya (14603468)

    Published 2021
    “…</p><h3>Conclusions</h3><p dir="ltr">Apoproteins apoA2, apoC1, apoC3 and apoE are decreased in women with GDM and may have a role in inflammation, as apoA2 and C3 correlated with CRP. …”
  4. 4

    Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex by Wesam S. Ahmed (10170053)

    Published 2022
    “…<p dir="ltr">Coronavirus Disease of 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has resulted in a massive health crisis across the globe, with some genetic variants gaining enhanced infectivity and competitive fitness, and thus significantly aggravating the global health concern. …”
  5. 5

    Notch Signaling Inhibition by LY411575 Attenuates Osteoblast Differentiation and Decreased Ectopic Bone Formation Capacity of Human Skeletal (Mesenchymal) Stem Cells by Nihal AlMuraikhi (6002234)

    Published 2019
    “…Among the tested molecules, LY411575, a potent γ-secretase and Notch signaling inhibitor, exhibited significant inhibitory effects on osteoblastic differentiation of hBMSCs manifested by reduced ALP activity, mineralized matrix formation, and decreased osteoblast-specific gene expression as well as in vivo ectopic bone formation. …”
  6. 6
  7. 7

    Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway by Olfa Khalifa (10914452)

    Published 2022
    “…<p dir="ltr">Non-alcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. …”
  8. 8

    The Anti-Tumor Agent Sodium Selenate Decreases Methylated PP2A, Increases GSK3βY216 Phosphorylation, Including Tau Disease Epitopes and Reduces Neuronal Excitability in SHSY-5Y Neu... by Wesal Habbab (17346961)

    Published 2019
    “…Somewhat surprisingly, the catalytically active form, methylated PP2A (mePP2A) was significantly decreased. In close correlation to these data, the phosphorylation state of two substrate proteins, sensitive to PP2A activity, GSK3β and Tau were found to be increased. …”
  9. 9

    Novel thiazolones for the simultaneous modulation of PPARγ, COX-2 and 15-LOX to address metabolic disease-associated portal inflammation by Mai S., El-Shoukrofy

    Published 2025
    “…A hybrid pharmacophore model, based on structural motifs previously identified by our team, was employed to generate ligands that simultaneously target COX-2, 15-LOX, and PPARγ in the context of metabolic dysfunction-associated fatty liver disease (MAFLD). Notable COX-2 inhibitory activities (IC50 = 0.065–0.24 μM) were observed relative to celecoxib (IC50 = 0.049 μM). …”
    Get full text
    Get full text
    Get full text
    article
  10. 10

    Interleukin-35 and Thymoquinone nanoparticle-based intervention for liver protection against paracetamol-induced liver injury in rats by Maisa Siddiq Abduh (16381125)

    Published 2023
    “…<p>Paracetamol (PAR) is a commonly used antipyretic and analgesic agent, but its excessive usage can induce liver damage and major health consequences. Interleukin-35 (IL-35) is utilized to treat immunological disorders, intestinal illness, arthritis, allergic disease, hepatitis, and cancer. …”
  11. 11

    Iron Overload in a Patient with Non-Transfusion-Dependent Hemoglobin H Disease and Borderline Serum Ferritin: Can We Rely on Serum Ferritin for Monitoring in This Group of Patients... by Mohammad Ali (73095)

    Published 2020
    “…Here we present an interesting case of a patient with hemoglobin H disease, who was monitored with serum ferritin. She had a serum ferritin level considered as a borderline risk for morbidities secondary to iron overload, and an MRI of her liver (Ferriscan) showed significant iron deposition in the liver associated with increased risk of complications secondary to iron overload.…”
  12. 12

    A complex presentation of an uncommon disease: Gas-forming pyogenic liver abscess complicated by septic pulmonary emboli and muscle abscesses, a case report and review of the liter... by Aseel H. Alzibdeh (17317009)

    Published 2023
    “…Most cases are secondary to enteric pathogens that cause focal liver disease. Gas-forming pyogenic liver abscess (GFPLA) is a rare subgroup of PLA characterized by the presence of gas within the abscess. …”
  13. 13

    The Superiority of T2*MRI Over Serum Ferritin in the Evaluation of Secondary Iron Overload in a Chronic Kidney Disease Patient: A Case Report by Abdulrahman Al-Mashdali (16388474)

    Published 2021
    “…Currently, T2*MRI of the heart and liver is the preferred investigation for evaluating liver iron concentration (LIC) and cardiac iron concentration, which reflect the state of iron overload. …”
  14. 14

    Novel thiazolones for the simultaneous modulation of PPARγ, COX-2 and 15-LOX to address metabolic disease-associated portal inflammation by Mai S. El-Shoukrofy (19646815)

    Published 2025
    “…<p dir="ltr">A hybrid pharmacophore model, based on structural motifs previously identified by our team, was employed to generate ligands that simultaneously target COX-2, 15-LOX, and PPARγ in the context of metabolic dysfunction-associated fatty liver disease (MAFLD). Notable COX-2 inhibitory activities (IC<sub>50</sub> = 0.065–0.24 μM) were observed relative to celecoxib (IC<sub>50</sub> = 0.049 μM). …”
  15. 15

    Investigation of the Effect of Exendin-4 on Oleic Acid-Induced Steatosis in HepG2 Cells Using Fourier Transform Infrared Spectroscopy by Olfa Khalifa (10914452)

    Published 2022
    “…<div><p>Non-alcoholic fatty liver disease (NAFLD) is a common liver lesion that is untreatable with medications. …”
  16. 16

    Artificial Intelligence for Detecting and Quantifying Fatty Liver in Ultrasound Images: A Systematic Review by Fahad Muflih Alshagathrh (18427950)

    Published 2022
    “…<div><p>Background: Non-alcoholic Fatty Liver Disease (NAFLD) is growing more prevalent worldwide. …”
  17. 17
  18. 18

    Comparative analysis of surgical management approaches for hydatid liver cysts: conventional vs. minimally invasive techniques by Walid Elmoghazy (17017716)

    Published 2023
    “…<h3>Introduction</h3><p dir="ltr">Hydatid liver disease is a prevalent condition in endemic areas, particularly in the Middle East and North Africa. …”
  19. 19

    AI-Based Multiclass Grading of Hepatic Steatosis From B-Mode Ultrasound: Generalization Across Modalities and Clinical Comparison With Radiologists by Fahad Muflih Alshagathrh (18427950)

    Published 2025
    “…<p dir="ltr">Non-alcoholic fatty liver disease (NAFLD) is a growing public health challenge, underscoring the need for scalable, non-invasive tools to grade hepatic steatosis. …”
  20. 20

    Indomethacin as a Rescue Therapy for Patent Ductus Arteriosus in Extremely Premature Infants after Failed Ibuprofen Treatment by Amal Sabouni (17046236)

    Published 2023
    “…<p dir="ltr">Hemodynamically significant patent ductus arteriosus (hsPDA) is a major cause of neonatal morbidity and mortality in extremely low birth weight (ELBW) infants. …”